GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Maxigen Biotech Inc (TPE:1783) » Definitions » EV-to-EBITDA

Maxigen Biotech (TPE:1783) EV-to-EBITDA : 17.65 (As of May. 19, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Maxigen Biotech EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Maxigen Biotech's enterprise value is NT$3,393.9 Mil. Maxigen Biotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was NT$192.3 Mil. Therefore, Maxigen Biotech's EV-to-EBITDA for today is 17.65.

The historical rank and industry rank for Maxigen Biotech's EV-to-EBITDA or its related term are showing as below:

TPE:1783' s EV-to-EBITDA Range Over the Past 10 Years
Min: -234.39   Med: 18.15   Max: 1014.56
Current: 17.65

During the past 13 years, the highest EV-to-EBITDA of Maxigen Biotech was 1014.56. The lowest was -234.39. And the median was 18.15.

TPE:1783's EV-to-EBITDA is ranked worse than
53.69% of 488 companies
in the Medical Devices & Instruments industry
Industry Median: 16.155 vs TPE:1783: 17.65

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-19), Maxigen Biotech's stock price is NT$43.60. Maxigen Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was NT$1.675. Therefore, Maxigen Biotech's PE Ratio for today is 26.03.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Maxigen Biotech EV-to-EBITDA Historical Data

The historical data trend for Maxigen Biotech's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maxigen Biotech EV-to-EBITDA Chart

Maxigen Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.29 12.53 26.55 16.55 17.54

Maxigen Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.82 21.46 19.90 17.54 18.57

Competitive Comparison of Maxigen Biotech's EV-to-EBITDA

For the Medical Instruments & Supplies subindustry, Maxigen Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maxigen Biotech's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Maxigen Biotech's EV-to-EBITDA falls into.



Maxigen Biotech EV-to-EBITDA Calculation

Maxigen Biotech's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=3393.937/192.318
=17.65

Maxigen Biotech's current Enterprise Value is NT$3,393.9 Mil.
Maxigen Biotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$192.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Maxigen Biotech  (TPE:1783) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Maxigen Biotech's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=43.60/1.675
=26.03

Maxigen Biotech's share price for today is NT$43.60.
Maxigen Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.675.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Maxigen Biotech EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Maxigen Biotech's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Maxigen Biotech (TPE:1783) Business Description

Traded in Other Exchanges
N/A
Address
No. 88, Keji 1st Rd, Guishan District, Taoyuan City, TWN, 333
Maxigen Biotech Inc specializes in the developing, manufacturing, and marketing of biomedical and cosmeceutical skincare products. It provides medical devices for orthopedic, ophthalmic, dental, and surgical applications. Skincare product categories include mask series, facial cleansing series, and body care series. The biomedical products segment is primarily engaged in the manufacturing and sales of collagen and bone materials, which forms the majority chunk of the revenue of the group. The consumer products segment is engaged in the manufacturing and sales of beauty care products.

Maxigen Biotech (TPE:1783) Headlines

No Headlines